lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Company profile
Ticker
LNTH
Exchange
Website
CEO
Mary Heino
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Lantheus MI Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Lantheus Medical Imaging, Inc. • Lantheus MI Canada, Inc. • Lantheus MI Real Estate, LLC • Lantheus MI UK Limited • Lantheus EU Limited • Lantheus Two, LLC • Lantheus Three, LLC • Progenics Pharmaceuticals, Inc. • Molecular Insight Pharmaceuticals, Inc. • MNTX Royalties Sub LLC ...
LNTH stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Mar 24
DEFA14A
Additional proxy soliciting materials
15 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Regulation FD Disclosure
26 Jan 24
8-K
Lantheus Announces CEO Succession Plan
23 Jan 24
8-K
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
9 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Lantheus Reports Third Quarter 2023 Financial Results
2 Nov 23
Transcripts
LNTH
Earnings call transcript
2023 Q4
22 Feb 24
LNTH
Earnings call transcript
2023 Q3
2 Nov 23
LNTH
Earnings call transcript
2023 Q2
3 Aug 23
LNTH
Earnings call transcript
2023 Q1
4 May 23
LNTH
Earnings call transcript
2022 Q4
23 Feb 23
LNTH
Earnings call transcript
2022 Q3
3 Nov 22
LNTH
Earnings call transcript
2022 Q2
7 Aug 22
LNTH
Earnings call transcript
2022 Q1
29 Apr 22
LNTH
Earnings call transcript
2021 Q4
24 Feb 22
LNTH
Earnings call transcript
2021 Q3
6 Nov 21
Latest ownership filings
4
Paul Blanchfield
19 Apr 24
4
Andrea Sabens
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
3
Amanda Michelle Morgan
4 Apr 24
4
Robert J. Jr. Marshall
19 Mar 24
4
Andrea Sabens
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Paul Blanchfield
11 Mar 24
4
Perspective Therapeutics, Inc.
8 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 396 |
Opened positions | 55 |
Closed positions | 86 |
Increased positions | 140 |
Reduced positions | 155 |
13F shares | Current |
---|---|
Total value | 4.83 tn |
Total shares | 71.08 mm |
Total puts | 2.37 mm |
Total calls | 920.80 k |
Total put/call ratio | 2.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.08 mm | $561.20 bn |
Vanguard | 6.99 mm | $485.60 bn |
JHG Janus Henderson | 3.09 mm | $214.70 bn |
STT State Street | 2.35 mm | $163.12 bn |
Alliancebernstein | 2.27 mm | $157.76 bn |
FMR | 2.15 mm | $149.11 bn |
Farallon Capital Management | 1.60 mm | $111.06 bn |
T. Rowe Price | 1.51 mm | $104.85 bn |
Geode Capital Management | 1.45 mm | $100.97 bn |
American Century Companies | 1.30 mm | $90.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Paul Blanchfield | Common Stock | Payment of exercise | Dispose F | No | No | 61.48 | 455 | 27.97 k | 102,677 |
15 Apr 24 | Andrea Sabens | Common Stock | Sell | Dispose S | No | Yes | 61.24 | 341 | 20.88 k | 63,239 |
15 Mar 24 | Robert J. Jr. Marshall | Common Stock | Sell | Dispose S | No | Yes | 60 | 20,000 | 1.20 mm | 113,749 |
13 Mar 24 | Andrea Sabens | Common Stock | Sell | Dispose S | No | Yes | 60.48 | 341 | 20.62 k | 63,204 |
News
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
19 Mar 24
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility; Financial Terms Not Disclosed
5 Mar 24
Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $82
26 Feb 24
Assessing Lantheus Holdings: Insights From 4 Financial Analysts
23 Feb 24
JMP Securities Reiterates Market Outperform on Lantheus Holdings, Maintains $100 Price Target
23 Feb 24
Press releases
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
28 Mar 24
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
28 Feb 24
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
26 Feb 24
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
13 Feb 24